Sumitomo Dainippon Pharma Oncology Announces First Patient Dosed in Phase 1 Dose Expansion Study of TP-1287 in Patients with Sarcoma
Wave 3 News,
Published: Nov. 3, 2021 at 8:00 AM EDT|Updated: 25 minutes ago CAMBRIDGE, Mass., Nov.
Published: Nov. 3, 2021 at 8:00 AM EDT|Updated: 25 minutes ago CAMBRIDGE, Mass., Nov.
Published: Nov. 3, 2021 at 7:00 AM CDT|Updated: 25 minutes ago CAMBRIDGE, Mass., Nov.
Published: Nov. 3, 2021 at 7:00 AM CDT|Updated: 24 minutes ago CAMBRIDGE, Mass., Nov.
CAMBRIDGE, Mass., Nov. 3, 2021 /PRNewswire/ Sumitomo Dainippon Pharma Oncology, Inc., a clinical-stage company focused on…
CAMBRIDGE, Mass., Nov. 3, 2021 /PRNewswire/ -- Sumitomo Dainippon Pharma Oncology, Inc., a clinical-stage company focused on…
CAMBRIDGE, Mass., Nov. 3, 2021 /PRNewswire/ -- Sumitomo Dainippon Pharma Oncology, Inc., a clinical-stage company focused on…
CAMBRIDGE, Mass., Nov. 3, 2021 /PRNewswire/ --Sumitomo Dainippon Pharma Co., Ltd.